GSK symposium on Restless Legs Syndrome for Requip.
Published: 2006-03-24 06:57:00
Updated: 2006-03-24 06:57:00
GSK Korea took a scientific symposium on Requip (ropinirole hydrochloride), the first FDA approved new drug for the treatment of the restless legs syndrome (RLS), by inviting Korean neuro and psychiatric physicians on March 16 and 17.
The symposium provided many useful informations about RLS, ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
